
Aligos Therapeutics, Inc.
Formerly Aligos, Inc.
Aligos Therapeutics, Inc. is listed today as Aligos Therapeutics, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 2 other private sales on record. Open the number of investors for the round's details.
Funding rounds of Aligos Therapeutics, Inc.| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|
| Feb 2025 | $105 M | Private placement after listing | $50 to $250 million | | equity, options | SEC |
| Oct 2023 | $92 M | Private placement after listing | $50 to $250 million | | equity, options | SEC |
| Dec 2019 | $85 M | No. 1 | $50 to $250 million | | equity | SEC |
What its filings and its own website say, sentence by sentence, each with its source.
Aligos Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Feb 2025).
SEC Form D · Feb 2025
The industry group it chose in its notices: Biotechnology.
SEC Form D · Feb 2025
No products or services of Aligos Therapeutics, Inc. are on record.
8 named in official filings. Open an investor to see everything it has backed.
Investors in Aligos Therapeutics, Inc.| Investor | Kind | Amount | Round | Role | Source |
|---|
| Julian A. Symons | Person | not stated | not stated | Held Series A, B-1 and B-2 preferred stock (Form 3, 2020) | SEC Form 3 |
| Novo Holdings A/s | Fund or asset manager | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Versant Vantage I, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Versant Venture Capital VI, L.P. | Venture capital | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Vivo Capital Fund VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Vivo Capital Surplus Fund VIII, L.P. | Fund or asset manager | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Vivo Capital VIII, LLC | Fund or asset manager | not stated | not stated | Held Series A, B-1 and B-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
| Wellington Biomedical Innovation Master Investors (Cayman) I L.P. | Fund or asset manager | not stated | not stated | Held Series B-1 and B-2 preferred stock, 10% owner (Form 3, 2020) | SEC Form 3 |
Largest shareholders today
Institutions holding Aligos Therapeutics, Inc. shares, as of Sep 30, 2026.
As of Sep 30, 2026
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
People named by Aligos Therapeutics, Inc.| Name | Role | Named in |
|---|
| Hardean Peter Achneck | Executive officer | Feb 2025 |
| Julian Peter Symons | Executive officer | Feb 2025 |
| Lawrence M. Blatt | President and Chief Executive Officer | Feb 2025 |
| Lesley Ann Calhoun | Executive Vice President, Chief Operating Officer and Chief Financial Officer | Feb 2025 |
| Julian Ann Symons | Executive Vice President, Chief Scientific Officer | Nov 2023 |
| Lawrence Blatt | Chief Executive Officer | Nov 2023 |
| Leonid Beigelman | President | Nov 2023 |
| Lucinda Ann Quan | Executive Vice President, Chief Business Officer and General Counsel | Nov 2023 |
| Matthew Ann McClure | Executive Vice President, Chief Medical Officer | Nov 2023 |
| Brian Dowd | Executive Vice President - Controller | Jan 2020 |
| John Fry | Executive Vice President - Clinical Development | Jan 2020 |
| Julian Symons | Executive Vice President - Chief Scientific Officer | Jan 2020 |
| Lucinda Quan | Executive Vice President - General Counsel | Jan 2020 |
| Sushmita Chanda | Executive Vice President - Preclinical Development | Jan 2020 |
| Bridget Peter Martell | Director | Feb 2025 |
| Carole Peter Nuechterlein | Director | Feb 2025 |
| Heather Peter Preston | Director | Feb 2025 |
| James Peter Scopa | Director | Feb 2025 |
| K. Peter Hirth | Director | Feb 2025 |
| Lawrence M. Blatt | President and Chief Executive Officer | Feb 2025 |
| Margarita Peter Chavez | Director | Feb 2025 |
| Bridget Ann Martell | Director | Nov 2023 |
| Carole Ann Nuechterlein | Director | Nov 2023 |
| Jack Ann Nielsen | Director | Nov 2023 |
| James Ann Scopa | Director | Nov 2023 |
| Lawrence Blatt | Chief Executive Officer | Nov 2023 |
| Leonid Beigelman | President | Nov 2023 |
| Peter Ann Hirth | Director | Nov 2023 |
| Carole Neuchterlein | Director | Jan 2020 |
| Jack Nielsen | Director | Jan 2020 |
| Kathleen Glaub | Director | Jan 2020 |
| Michael Yi | Director | Jan 2020 |
| Peter Hirth | Director | Jan 2020 |
| Peter Moldt | Director | Jan 2020 |
| Tom Woiwode | Director | Jan 2020 |
Went public since 2020. Its SEC number is that of a company listed on a stock exchange.